

DAFTAR PUSTAKA

1. Castle M, Ajemian E. Hospital Infection Control : Principles and Practice, 2 ed. Canada: John Wiley & Sons, Inc., 1987.
2. Buku Ajar Ilmu Penyakit Dalam 4ed. Vol. 1. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia, 2006.
3. Porth C. Pathophysiology, 5 ed. Philadelphia: Lippincott-Raven, 1998.
4. Melaku S, Kibret M, Abera B, Gebre-Sellassie S. Antibigram of nosocomial urinary tract infections in Felege Hiwot referral hospital, Ethiopia. *Afr Health Sci* 2012;12(2):134-9.
5. Sahm DF, Thornsberry C, Mayfield DC, et al. Multidrug-resistant urinary tract isolates of *Escherichia coli*: prevalence and patient demographics in the United States in 2000. *Antimicrob Agents Chemother* 2001;45(5):1402-6.
6. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. *Am J Med* 2002;113 Suppl 1A:5S-13S.
7. Istanto T. Faktor Risiko, Pola Kuman, dan Tes Kepekaan Antibiotik pada Penderita Infeksi Saluran Kemih di RS Dr. Kariadi Semarang tahun 2004-2005. Fakultas Kedokteran. Semarang: Universitas Diponegoro, 2006.
8. Boyle B, al e. Guidelines for Control and Prevention of Multidrug-resistant Organism (MDRO) Excluding MRSA in The Healthcare Setting 2011.

9. D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. *Infect Control Hosp Epidemiol* 2004;25(10):842-6.
10. BJ Gossett RNC, LeMire JM, William S. Nakashima M, et al. Guidelines for Prevention and Control of Infections Due to Antibiotic-Resistant Organisms. In: Health FDo, ed. Florida, 2010.
11. Rosenbaum P, Aureden K, Cloughessy M, et al. Guide to the Elimination of Multidrug-resistant *Acinetobacter baumannii* Transmission in Healthcare Settings. Apic 2010.
12. Derricott B. Multi-Drug Resistant Organisms. Wild Iris Medical Education, 2011.
13. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. *J Antimicrob Chemother* 2010;65 Suppl 3:iii25-33.
14. Cohen AL, Calfee D, Fridkin SK, Huang SS. Recommendations for Metrics for Multidrug-Resistant Organisms in Healthcare Settings: SHEA/HICPAC Position Paper. 2008.
15. Geffers C, Gastmeier P. Nosocomial Infections and Multidrug-resistant Organisms in Germany. *Deutsches Ärzteblatt International* 2011.
16. Archibald L, Phillips L, Monnet D, et al. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. *Clin Infect Dis* 1997;24(2):211-5.


17. Karina Billote-Domingo MD, Myrna T. Mendoza, M.D., Tessa Tan Torres, M.D. Catheter-related Urinary Tract Infections: Incidence, Risk Factors and Microbiologic Profile. 1998;28.
18. Dhanardhono T. Risk Factor Associated with Urinary Tract Infection in Geriatric and Its Microbiologic Characteristics. Faculty of Medicine. Semarang: Diponegoro University, 2006.
19. Amna MA, Chazan B, Raz R, et al. Risk factors for non-Escherichia coli community-acquired bacteriuria. 2012.
20. Kasper DL, Braunwald E, Fauci AS. Harrison's Principle of Internal Medicine, 16 ed: Mc Graw-Hill Companies. inc, 2005.
21. Purnomo BB. Dasar-dasar Urologi 2ed. Jakarta: Sagung Seto, 2003.
22. Elderly Urinary Tract Infections. 2012.
23. Sax H, Harbarth S, Gavazzi G, et al. Prevalence and prediction of previously unknown MRSA carriage on admission to a geriatric hospital. Age Ageing 2005;34(5):456-62.
24. Wheat LJ. Infection and Diabetes Mellitus. Diabetes Care 1980;3.
25. Davis NF, Flood HD. The Pathogenesis of Urinary Tract Infections. Intech Journal.
26. Warren JW. Catheter-associated urinary tract infections. Int J Antimicrob Agents 2001;17(4):299-303.
27. Engel LS. Multidrug-Resistant Gram-Negative Bacteria: Trends, Risk Factors, and Treatments. 2009.

28. Urinary Tract Infection. v. 2013.
29. Collignon P. Resistant Escherichia coli We Are What We Eat. America: Infectious Diseases Society of America, 2009.
30. Joshi M. Urinary Tract Infection in the Intensive Care Unit: A Common Occurrence, but With Minimal Clarity. 2007.
31. Eickhoff TC. Antibiotics and nosocomial infections. Boston: Little, Brown & Co., 1992.
32. Lipsitch M, Samore MH. Antimicrobial Use and Antimicrobial Resistance: A Population Perspective. CDC, 2002; v. 8.
33. Donowitz LG, Wenzel RP, Hoyt JW. High risk of hospital-acquired infection in the ICU patient. Crit Care Med 1982;10(6):355-7.
34. Kassis-Chikhani N, Vimont S, Asselat K, et al. CTX-M beta-lactamase-producing Escherichia coli in long-term care facilities, France. Emerg Infect Dis 2004;10(9):1697-8.
35. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1991;281.
36. Smith PW, Rusnak PG. Infection prevention and control in the long-term-care facility. SHEA Long-Term-Care Committee and APIC Guidelines Committee. Am J Infect Control 1997;25(6):488-512.
37. Viray M, Linkin D, Maslow JN, et al. Longitudinal trends in antimicrobial susceptibilities across long-term-care facilities: emergence of fluoroquinolone resistance. Infect Control Hosp Epidemiol 2005;26(1):56-62.

38. Strausbaugh LJ, Crossley KB, Nurse BA, Thrupp LD. Antimicrobial resistance in long-term-care facilities. *Infect Control Hosp Epidemiol* 1996;17(2):129-40.
39. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. *Clin Infect Dis* 1999;29(3):490-4.
40. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. *Clin Infect Dis* 1992;14(6):1201-7.
41. Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. *Lancet* 1995;345(8965):1607-9.
42. Vandecasteele SJ, Boelaert JR, De Vriese AS. Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. *Clin J Am Soc Nephrol* 2009;4(8):1388-400.
43. Boelaert JR, Daneels RF, Schurgers ML, et al. Iron overload in haemodialysis patients increases the risk of bacteraemia: a prospective study. *Nephrol Dial Transplant* 1990;5(2):130-4.
44. Zimmerli W, Lew PD, Waldvogel FA. Pathogenesis of foreign body infection. Evidence for a local granulocyte defect. *J Clin Invest* 1984;73(4):1191-200.
45. Gadepalli R, Dhawan B, Sreenivas V, et al. A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. *Diabetes Care* 2006;29(8):1727-32.

46. Banashankari GS, Rudresh HK, Harsha AH. Prevalence of Gram Negative Bacteria in Diabetic Foot - A Clinico-Microbiological Study. US National Library of Medicine enlisted 2012.
47. Zubair M, Malik A, Ahmad J. Clinico-bacteriology and risk factors for the diabetic foot infection with multidrug resistant microorganisms in north India. *Biology and Medicine* 2010.
48. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. *Clin Infect Dis* 2004;38(1):17-24.
49. Jawetz E, Melnick J, Adelberg E. *Review of Medical Microbiology*, 15 ed. Singapore: Hunstmen Offset Printing Pte, Ltd., 1982.
50. Wright SW, Wrenn KD, Haynes M, Haas DW. Prevalence and risk factors for multidrug resistant uropathogens in ED patients. *Am J Emerg Med* 2000;18(2):143-6.
51. Arstila T, Huovinen S, Lager K, et al. Positive correlation between the age of patients and the degree of antimicrobial resistance among urinary strains of *Escherichia coli*. *J Infect* 1994;29(1):9-16.
52. Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant *Escherichia coli*. *J Urol* 1995;153(1):117-20.
53. Maki DG, Tambyah PA. Engineering out the risk for infection with urinary catheters. *Emerg Infect Dis* 2001;7(2):342-7.

54. Trautner BW, Darouiche RO. Catheter-associated infections: pathogenesis affects prevention. *Arch Intern Med* 2004;164(8):842-50.
55. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant *Streptococcus pneumoniae*: a multicenter study. *Clin Infect Dis* 1997;24(6):1052-9.
56. Abbo A, Navon-Venezia S, Hammer-Muntz O, et al. Multidrug-resistant *Acinetobacter baumannii*. *Emerg Infect Dis* 2005;11(1):22-9.
57. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. *Arch Intern Med* 2008;168(20):2205-10.
58. Doern GV, Ferraro MJ, Brueggemann AB, Ruoff KL. Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States. *Antimicrob Agents Chemother* 1996;40(4):891-4.
59. Bantar C, Fernandez Canigia L, Relloso S, et al. Species belonging to the "Streptococcus milleri" group: antimicrobial susceptibility and comparative prevalence in significant clinical specimens. *J Clin Microbiol* 1996;34(8):2020-2.
60. Hartemann-Heurtier A, Robert J, Jacqueminet S, et al. Diabetic foot ulcer and multidrug-resistant organisms: risk factors and impact. *Diabet Med* 2004;21(7):710-5.



Your complimentary
use period has ended.
Thank you for using
PDF Complete.

[Click Here to upgrade to
Unlimited Pages and Expanded Features](#)

61. L'Heriteau F, Alberti C, Cohen Y, et al. Nosocomial infection and multidrug-resistant bacteria surveillance in intensive care units: a survey in France. *Infect Control Hosp Epidemiol* 2005;26(1):13-20.